{"organizations": [], "uuid": "f97877091571e817cefd9c711680f50a15cfe7cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-rejects-filing-for-celgene-ms/brief-fda-rejects-filing-for-celgene-ms-drug-idUSASB0C7UO", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA rejects filing for Celgene MS drug", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T00:12:00.000+02:00", "replies_count": 0, "uuid": "f97877091571e817cefd9c711680f50a15cfe7cf"}, "author": "", "url": "https://www.reuters.com/article/brief-fda-rejects-filing-for-celgene-ms/brief-fda-rejects-filing-for-celgene-ms-drug-idUSASB0C7UO", "ord_in_thread": 0, "title": "BRIEF-FDA rejects filing for Celgene MS drug", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-fda", "sentiment": "negative"}, {"name": "celgene", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "celgene corp", "sentiment": "none"}, {"name": "celgene corp", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "co", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 27 (Reuters) - Celgene Corp:\n* CELGENE PROVIDES REGULATORY UPDATE ON OZANIMOD FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS\n* CELGENE CORP - ‍FDA DETERMINED NONCLINICAL AND CLINICAL PHARMACOLOGY SECTIONS IN NDA WERE INSUFFICIENT TO PERMIT A COMPLETE REVIEW​\n* CELGENE - CO INTENDS TO SEEK IMMEDIATE GUIDANCE, INCLUDING REQUESTING A TYPE A MEETING WITH FDA\n* CELGENE - GOT REFUSAL TO FILE LETTER FROM FDA ABOUT CO‘S NDA FOR OZANIMOD IN DEVELOPMENT FOR TREATING PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS\n* CELGENE - ‍SEEKING GUIDANCE WHICH INCLUDES REQUESTING MEETING WITH FDA, TO ASCERTAIN WHAT ADDITIONAL DATA WILL BE REQUIRED TO RESUBMIT NDA​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-28T00:12:00.000+02:00", "crawled": "2018-02-28T00:34:18.026+02:00", "highlightTitle": ""}